Reidy K, et al.. Molecular mechanisms of diabetic kidney disease. J Clin Invest 2014; 124:2333–2340.
Gregg EW, Williams DE, Geiss L. Changes in diabetes-related complications in the United States. N Engl J Med 2014; 371:286–287.
Tervaert TW, et al.. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21:556–563.
National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 Update. Am J Kidney Dis 2015; 66:884–930.
Perkins BA, et al.. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285–2293.
Sharma SG, et al.. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8:1718–1724.
Handelsman Y, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract 2015; 21[Suppl 1]:1–87.
Marso SP, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–322.
Wanner C, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323–334.
Zinman B, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128.
Heerspink HJ, et al.. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28(1):368–375.